| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Activated CDC42 kinase 1; ACK-1; EC=2.7.10.2; EC=2.7.11.1; Tyrosine kinase non-receptor protein 2 |
| Entrez GeneID | 10188; |
| WB Predicted band size | 115kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from Internal of human ACK1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ACK1(Ab-284)抗体的3篇参考文献(经概括整理)：
1. **文献名称**：*Targeting ACK1 signaling inhibits prostate cancer progression*
**作者**：Mahajan K, et al.
**摘要**：该研究报道了ACK1激酶通过磷酸化雄激素受体(AR)促进前列腺癌细胞存活。使用ACK1抗体(如Ab-284)或抑制剂可阻断AR信号通路，抑制肿瘤生长并诱导癌细胞凋亡。
2. **文献名称**：*ACK1/TNK2 regulates receptor tyrosine kinase degradation in cancer*
**作者**：Prieto-Echagüe V, et al.
**摘要**：文章揭示了ACK1通过泛素化调控EGFR等受体酪氨酸激酶的稳定性。ACK1抗体(Ab-284)在实验中用于检测ACK1蛋白表达水平，并验证其在乳腺癌模型中对肿瘤转移的抑制作用。
3. **文献名称**：*Structural basis of ACK1 kinase activation and inhibition*
**作者**：Lin J, et al.
**摘要**：通过晶体结构分析，阐明了ACK1激酶域的构象变化机制。研究利用Ab-284抗体进行免疫共沉淀实验，证实特定抑制剂结合ACK1后可阻断其与下游效应分子相互作用。
**注**：文献中Ab-284常作为工具抗体用于检测ACK1蛋白或验证功能，其应用多聚焦于癌症信号通路机制研究。部分研究可能涉及抗体与小分子抑制剂的联合使用。
ACK1 (Activated Cdc42-associated kinase 1), also known as TNK2. is a non-receptor tyrosine kinase implicated in regulating multiple signaling pathways, including those involving the androgen receptor (AR) and epidermal growth factor receptor (EGFR). It plays a critical role in cell proliferation, survival, and migration, with dysregulation linked to cancer progression, particularly in prostate, breast, and lung cancers. Overexpression or hyperactivation of ACK1 is associated with tumor growth, metastasis, and therapy resistance, making it a promising therapeutic target.
The ACK1 (Ab-284) antibody is a monoclonal antibody designed to specifically target and inhibit ACK1 kinase activity. By binding to ACK1. it blocks downstream signaling cascades, such as phosphorylation of AR or AKT, thereby suppressing oncogenic processes. Preclinical studies highlight its potential in reducing tumor growth and enhancing the efficacy of existing therapies, especially in hormone-resistant cancers. Researchers also utilize Ab-284 as a tool to study ACK1's functional roles in cellular models and disease mechanisms.
Currently, ACK1 inhibitors, including antibody-based approaches like Ab-284. are under investigation as novel anticancer agents. Their development addresses the need for therapies targeting kinase-driven malignancies and overcoming drug resistance. While clinical data remain limited, ongoing research continues to explore its translational potential, positioning ACK1 (Ab-284) as both a therapeutic candidate and a valuable reagent in cancer biology studies.
×
